Global Immunomodulators Market Overview, Trends, Opportunities, Growth and Forecast by 2021-2026

According to the latest report by IMARC Group, titled “Immunomodulators Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global immunomodulators market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 6% during 2021-2026.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request Free Report Sample:

Immunomodulators refer to a group of drugs that are commonly prescribed to modify an immune response against immunodeficiency, infectious diseases and alterations in antibody transfer. These medicines are used for the treatment of asthma, cancer, tumors and autoimmune disorders. Some of these drugs include cytokines, levamisole, monoclonal antibodies and Bacillus Calmette-Guerin (BCG).

The global market is majorly driven by the increasing incidences of numerous chronic diseases among the masses. This can be attributed to the growing geriatric population, sedentary lifestyles led by individuals and their changing dietary preferences. Additionally, there has been a considerable rise in the prevalence of severe road accidents, which has boosted the demand for immunomodulators as a crucial agent in organ transplant procedures. Furthermore, multiple immunomodulators, including Tocilizumab, Fluvoxamine, and Baricitinib with Remdesivir, are widely being prescribed by healthcare professionals for the treatment of patients suffering from the coronavirus disease (COVID-19). The rapid outbreak of COVID-19 across the globe is providing an impetus to the market growth.

Immunomodulators Market 2021-2026 Competitive Analysis and Segmentation:

Competitive Landscape with Key Players:

The competitive landscape of the global immunomodulators market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

Key Market Segmentation:

The report has segmented the global immunomodulators market on the basis of product, application and region.

Breakup by Product:

  • Immunosuppressants
  • Immunostimulants

Breakup by Application:

  • Oncology
  • Respiratory
  • HIV
  • Others

Breakup by Region:

  • North America
  • Asia-Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Explore Full Report with TOC & List of Figure:

Key highlights of the report:            

  • Market Performance (2015-2020)
  • Market Outlook (2021-2026)
  • Industry Trends
  • Market Drivers and Success Factors
  • The Impact of COVID-19 on the Global Market
  • Value Chain Analysis
  • Structure of the Global Market
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us                              

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

30 N Gould St, Ste R
Sheridan, WY 82801, USA
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800




Comments are closed